Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 2

Conditions

Neoplasms 5Neoplasm Metastasis 4Breast Neoplasms 4Non-small Cell Lung Cancer Metastatic 1Colorectal Neoplasms 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Neoplasms × AZD 8931 × Clear all
NCT00900627 2016-01-20

THYME

AstraZeneca

Phase 1/2 Completed
330 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01579578 2014-09-12

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

AstraZeneca

Phase 2 Terminated
39 enrolled 12 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01151215 2014-07-25

MINT

AstraZeneca

Phase 2 Terminated
482 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01003158 2014-07-10

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

AstraZeneca

Phase 1 Completed
17 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00637039 2013-03-12

Study of AZD8931 in Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡